NO20061071L - Kimeriske antigener for a odelegge vertstoleranse mot fremmede antigener - Google Patents

Kimeriske antigener for a odelegge vertstoleranse mot fremmede antigener

Info

Publication number
NO20061071L
NO20061071L NO20061071A NO20061071A NO20061071L NO 20061071 L NO20061071 L NO 20061071L NO 20061071 A NO20061071 A NO 20061071A NO 20061071 A NO20061071 A NO 20061071A NO 20061071 L NO20061071 L NO 20061071L
Authority
NO
Norway
Prior art keywords
antigens
foreign
antigen
immune response
chimeric
Prior art date
Application number
NO20061071A
Other languages
English (en)
Norwegian (no)
Inventor
Antoine A Noujaim
Rajan George
Lorne Tyrrell
Dakum Wang
Allan Ma
Original Assignee
Virexx Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virexx Medical Inc filed Critical Virexx Medical Inc
Publication of NO20061071L publication Critical patent/NO20061071L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO20061071A 2003-08-08 2006-03-06 Kimeriske antigener for a odelegge vertstoleranse mot fremmede antigener NO20061071L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49344903P 2003-08-08 2003-08-08
PCT/CA2004/001469 WO2005014838A1 (en) 2003-08-08 2004-08-06 Chimeric antigens for breaking host tolerance to foreign antigens

Publications (1)

Publication Number Publication Date
NO20061071L true NO20061071L (no) 2006-05-08

Family

ID=34135247

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061071A NO20061071L (no) 2003-08-08 2006-03-06 Kimeriske antigener for a odelegge vertstoleranse mot fremmede antigener

Country Status (17)

Country Link
US (1) US8007805B2 (zh)
EP (2) EP2213742B1 (zh)
JP (1) JP5200201B2 (zh)
KR (2) KR20120102167A (zh)
CN (1) CN1845995B (zh)
AU (1) AU2004263561A1 (zh)
BR (1) BRPI0413314A (zh)
CA (1) CA2534911C (zh)
EA (1) EA013070B1 (zh)
HK (1) HK1091512A1 (zh)
IL (1) IL173302A0 (zh)
MX (1) MXPA06001449A (zh)
NO (1) NO20061071L (zh)
NZ (1) NZ545048A (zh)
TW (1) TWI364294B (zh)
WO (1) WO2005014838A1 (zh)
ZA (1) ZA200600804B (zh)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8025873B2 (en) * 2002-06-20 2011-09-27 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
EP2845865A1 (en) * 2004-11-12 2015-03-11 Xencor Inc. Fc variants with altered binding to FcRn
CN101300355A (zh) * 2005-10-13 2008-11-05 威瑞克斯医药公司 包含丙型肝炎病毒多肽和用于引起免疫应答的Fc片段的嵌合抗原
GB0605735D0 (en) * 2006-03-22 2006-05-03 Immunobiology Ltd Composition and method for mediating an immune response
GB0615266D0 (en) * 2006-08-01 2006-09-06 Immunobiology Ltd Composition and method for mediating an immune response
EP2129394B1 (en) * 2007-03-09 2012-06-20 Merck Sharp & Dohme Corp. Papillomavirus vaccine compositions
KR20100047343A (ko) * 2007-08-30 2010-05-07 바이렉스 메디칼 코포레이션 항원 조성물 및 핵산의 표적화된 전달에서의 이의 용도
US20090305611A1 (en) * 2008-06-06 2009-12-10 Flow International Corporation Device and method for improving accuracy of a high-pressure fluid jet apparatus
CA2770075C (en) * 2009-08-07 2021-08-24 Perrine Martin Composition for treating hbv infection
EP2335721A1 (en) * 2009-12-21 2011-06-22 Institut Pasteur Streptavidin and Biotin-based antigen delivery system
US9518087B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9238679B2 (en) * 2011-02-11 2016-01-19 The Trustees Of The University Of Pennslyvania Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same
US9238683B2 (en) 2011-02-23 2016-01-19 University Of Maryland College Park Efficient mucosal vaccination mediated by the neonatal Fc receptor
EP3138581B1 (en) 2011-03-17 2019-01-02 The University of Birmingham Re-directed immunotherapy
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
CA2878427A1 (en) 2012-07-26 2014-01-30 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Multimeric fusion protein vaccine and immunotherapeutic
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
EP3909603A1 (en) 2014-02-21 2021-11-17 Ecole Polytechnique Fédérale de Lausanne (EPFL) Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
CN106572645A (zh) * 2014-06-12 2017-04-19 中央大学校产学协力团 用于制备产生免疫原性复合蛋白的转基因植物的方法及由其获得的免疫原性复合蛋白
US10441649B2 (en) 2015-02-02 2019-10-15 The University Of Birmingham Targeting moiety peptide epitope complexes having a plurality of T-cell epitopes
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
CN104829732A (zh) * 2015-03-25 2015-08-12 温州医科大学 一种重组蛋白及其在昆虫杆状病毒表达系统中的表达方法
CN108290960B (zh) 2015-10-08 2023-06-09 艾伯塔大学理事会 丙型肝炎病毒e1/e2异二聚体及其生产方法
ES2873846T3 (es) 2015-11-19 2021-11-04 Revitope Ltd Complementación de fragmento de anticuerpo funcional para un sistema de dos componentes para eliminación redirigida de células no deseadas
WO2018232176A1 (en) 2017-06-16 2018-12-20 The University Of Chicago Compositions and methods for inducing immune tolerance
EP3997132A4 (en) 2019-07-09 2022-12-14 Akshaya Bio Inc. CHIMERIC ANTIGENS FOR THE TREATMENT OF VIRUS INFECTIONS
BR112022003970A2 (pt) 2019-09-03 2022-06-21 Myeloid Therapeutics Inc Métodos e composições para integração genômica
WO2021119538A1 (en) * 2019-12-11 2021-06-17 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods for manufacture and uses thereof
EP4240367A2 (en) 2020-11-04 2023-09-13 Myeloid Therapeutics, Inc. Engineered chimeric fusion protein compositions and methods of use thereof

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4088748A (en) * 1976-11-02 1978-05-09 Merck & Co., Inc. Hepatitis B surface antigen
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4181713A (en) * 1978-10-30 1980-01-01 Merck & Co., Inc. Isolation of HBs Ag
FR2480779B2 (fr) * 1979-08-30 1986-07-18 Anvar Vecteur contenant une sequence nucleotidique de l'antigene de surface du virus de l'hepatite b et procede de fabrication d'une molecule immunogene mettant en oeuvre ce vecteur
US5196194A (en) * 1979-05-24 1993-03-23 The Regents Of The University Of California Vaccines containing Hepatitis B S-protein
US4433059A (en) * 1981-09-08 1984-02-21 Ortho Diagnostic Systems Inc. Double antibody conjugate
US4816249A (en) * 1981-11-17 1989-03-28 The Board Of Trustees Of The Leland Stanford Junior University Monoclonal anti-idiotype antibodies
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5053224A (en) * 1983-11-07 1991-10-01 Hilary Koprowski Induction of antibody response to solid tumors with anti-idiotype antibodies
US4599230A (en) * 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599231A (en) * 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US6808901B1 (en) * 1984-09-03 2004-10-26 Celltech R&D Limited Production of chimeric antibodies
US4722840A (en) * 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
US5019369A (en) * 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4569794A (en) * 1984-12-05 1986-02-11 Eli Lilly And Company Process for purifying proteins and compounds useful in such process
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5047513A (en) * 1986-07-10 1991-09-10 Hoffmann-La Roche Inc. Metal chelate resins
CA1304886C (en) * 1986-07-10 1992-07-07 Heinz Dobeli Metal chelate resins
US5260203A (en) * 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
CA1340522C (en) * 1987-03-10 1999-05-04 Heinz Dobeli Fusion proteins containing neighbouring histidines for improved purification
US6710169B2 (en) * 1987-10-02 2004-03-23 Genentech, Inc. Adheson variants
US5336603A (en) * 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US5567584A (en) 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US6018026A (en) 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
US5750375A (en) 1988-01-22 1998-05-12 Zymogenetics, Inc. Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
EP1762623A1 (en) 1988-01-22 2007-03-14 ZymoGenetics, Inc. Methods for producing biologically active peptide dimers
US6004781A (en) * 1988-01-22 1999-12-21 The General Hospital Corporation Nucleic acid encoding Ig-CD4 fusion proteins
AU3342689A (en) * 1988-03-24 1989-10-16 Igen Incorporated Luminescent chimeric proteins
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US6406697B1 (en) * 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
US5216131A (en) * 1989-02-23 1993-06-01 Genentech, Inc. Lymphocyte homing receptors
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5098833A (en) * 1989-02-23 1992-03-24 Genentech, Inc. DNA sequence encoding a functional domain of a lymphocyte homing receptor
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
JPH05500611A (ja) * 1989-08-23 1993-02-12 ザ・ジェネラル・ホスピタル・コーポレーション 非ヒト霊長類ｃｄ４ポリペプチド、グリコシル化可能なヒトｃｄ４分子、その断片、その融合タンパク質、その遺伝子配列および使用
US5969109A (en) * 1990-02-28 1999-10-19 Bona; Constantin Chimeric antibodies comprising antigen binding sites and B and T cell epitopes
HU218603B (hu) 1990-07-20 2000-10-28 Kabi Pharmacia Ab Célspecifikus antitest-szuperantigén konjugátumok és ezen készítmények előállítása
US6248332B1 (en) * 1990-10-05 2001-06-19 Medarex, Inc. Targeted immunostimulation with bispecific reagents
JP3583420B2 (ja) 1990-10-05 2004-11-04 メダレツクス・インコーポレーテツド 二特異的試薬を用いた標的免疫化
US6274148B1 (en) * 1990-11-08 2001-08-14 Chiron Corporation Hepatitis C virus asialoglycoproteins
JP3011510B2 (ja) * 1990-12-20 2000-02-21 株式会社東芝 相互連結回路基板を有する半導体装置およびその製造方法
US5346994A (en) * 1992-01-28 1994-09-13 Piotr Chomczynski Shelf-stable product and process for isolating RNA, DNA and proteins
US5928902A (en) * 1992-02-27 1999-07-27 Smithkline Beecham Biologicals (S.A.) Hybrid protein between CS from plasmodium and HBsAg
DK0992580T3 (da) * 1993-11-04 2005-07-11 Innogenetics Nv Epitoper på human T-celler, som er immundominante for hepatitis C-virus
US5817308A (en) * 1994-02-14 1998-10-06 University Of Rochester Tolerogenic fusion proteins of immunoglobulins and methods for inducing and maintaining tolerance
US5686600A (en) * 1994-06-28 1997-11-11 Novartis Finance Corporation Antibodies which bind to insect gut proteins and their use
SE9402430L (sv) 1994-07-11 1996-01-12 Pharmacia Ab Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
ATE235514T1 (de) * 1994-12-28 2003-04-15 Univ Kentucky Monoklonaler anti-idiotypischer antikörper 3h1 aus maus
JPH11506336A (ja) 1995-06-07 1999-06-08 コノート ラボラトリーズ リミテッド 免疫系選択細胞への抗原送達のためのキメラ抗体
GB9516760D0 (en) 1995-08-16 1995-10-18 Sandoz Ltd Organic compounds
TW517061B (en) 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
WO1997042973A1 (en) * 1996-05-15 1997-11-20 Altarex, Corp. Method and composition for reconforming multi-epitopic antigens to initiate an immune response
CN1201005C (zh) * 1996-05-22 2005-05-11 维文蒂阿生物技术股份有限公司 特异性检测癌细胞的抗原结合片段、编码所述片段的dna、以及它们在预防和检测癌症上的用途
EP0839915A1 (en) 1996-11-01 1998-05-06 Institut Suisse De Recherches Experimentales Sur Le Cancer Isrec Secretory immunoglobulin A as a mucosal vaccine delivery system
US6277375B1 (en) * 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
AU7471698A (en) * 1997-05-06 1998-11-27 Chiron Corporation Intracellular production of hepatitis c e1 and e2 truncated polypeptides
US6242195B1 (en) * 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
US7090976B2 (en) * 1999-11-10 2006-08-15 Rigel Pharmaceuticals, Inc. Methods and compositions comprising Renilla GFP
WO1999061630A2 (en) * 1998-05-26 1999-12-02 Regeneron Pharmaceuticals, Inc. Chimeric molecules comprising an extracellular ligand binding domain of a receptor and an ige fc or constant region, and their use in an assay system
IL139832A0 (en) 1998-06-15 2002-02-10 Altarex Inc Therapeutic compositions that produce an immune response by altering the antigen
EP1117691A1 (en) 1998-10-05 2001-07-25 Ludwig Institute For Cancer Research Methods for producing human tumor antigen specific antibodies
BR0010322A (pt) * 1999-05-06 2002-04-09 Univ Wake Forest Vetor de expressão, vacina e seu método de uso para eliciar uma resposta imune dirigida contra um antìgeno em um mamìfero
US7067110B1 (en) * 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US6716966B1 (en) 1999-08-18 2004-04-06 Altarex Corp. Therapeutic binding agents against MUC-1 antigen and methods for their use
GB9925966D0 (en) 1999-11-02 1999-12-29 Petrik Juraj Threapeutic vaccines against variable viruses and other targets
GB9926084D0 (en) 1999-11-03 2000-01-12 King S College London Recombinant fusion molecules
AU2001259063A1 (en) * 2000-04-12 2001-10-30 Human Genome Sciences, Inc. Albumin fusion proteins
JP2003532687A (ja) * 2000-05-11 2003-11-05 アルタレックス コーポレイション 抗原−抗体複合体化および樹状細胞による提示を利用する治療法および組成物
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
CN100343393C (zh) * 2002-03-15 2007-10-17 布赖汉姆妇女医院 适合治疗剂全身性递送的中央气道给药
US20040063912A1 (en) * 2002-03-15 2004-04-01 The Brigham And Women's Hospital, Inc. Central airway administration for systemic delivery of therapeutics
US8029803B2 (en) * 2002-06-20 2011-10-04 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
WO2004004798A2 (en) 2002-07-03 2004-01-15 The Brigham And Women's Hospital, Inc. Central airway administration for systemic delivery of therapeutics
WO2004100882A2 (en) 2003-05-06 2004-11-25 Syntonix Pharmaceuticals, Inc. Inhibition of drug binding to serum albumin
WO2004108885A2 (en) 2003-05-06 2004-12-16 Syntonix Pharmaceuticals, Inc. Fc chimeric proteins with anti-hiv drugs
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
EP2298347B1 (en) 2003-05-06 2015-09-30 Biogen Hemophilia Inc. Clotting factor chimeric proteins for treatment of a hemostatic disorder
JP2008504012A (ja) 2004-01-28 2008-02-14 シントニックス・ファーマシューティカルズ・インコーポレーテッド 不妊治療のためのへテロ二量体卵胞刺激ホルモン−Ｆｃ（ＦＳＨ−Ｆｃ）融合タンパク質
CN101300355A (zh) * 2005-10-13 2008-11-05 威瑞克斯医药公司 包含丙型肝炎病毒多肽和用于引起免疫应答的Fc片段的嵌合抗原

Also Published As

Publication number Publication date
EP1664270A1 (en) 2006-06-07
WO2005014838A1 (en) 2005-02-17
KR20120102167A (ko) 2012-09-17
KR101327719B1 (ko) 2013-11-12
EP2213742B1 (en) 2016-01-06
ZA200600804B (en) 2007-04-25
KR20060089719A (ko) 2006-08-09
HK1091512A1 (zh) 2007-01-19
US8007805B2 (en) 2011-08-30
EP1664270A4 (en) 2006-09-06
EP1664270B1 (en) 2014-05-21
EA013070B1 (ru) 2010-02-26
EP2213742A1 (en) 2010-08-04
EA200600390A1 (ru) 2006-08-25
JP5200201B2 (ja) 2013-06-05
JP2007501602A (ja) 2007-02-01
CN1845995A (zh) 2006-10-11
IL173302A0 (en) 2006-06-11
CA2534911C (en) 2018-10-02
AU2004263561A1 (en) 2005-02-17
TW200515916A (en) 2005-05-16
CA2534911A1 (en) 2005-02-17
NZ545048A (en) 2009-06-26
BRPI0413314A (pt) 2006-10-10
US20050031628A1 (en) 2005-02-10
TWI364294B (en) 2012-05-21
CN1845995B (zh) 2011-04-27
MXPA06001449A (es) 2006-08-25

Similar Documents

Publication Publication Date Title
NO20061071L (no) Kimeriske antigener for a odelegge vertstoleranse mot fremmede antigener
TW200732346A (en) Chimeric hepatitis C virus antigens for eliciting an immune response
NO20072253L (no) Forbedrede vaksiner
EP1198250B8 (en) Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
NO20065874L (no) Antistoffer og beslektede molekyler som bindes til PSCA proteiner
NO20083266L (no) Humane anti-IL-23-antistoffer, sammensetninger, fremgangsmater og anvendelser
NZ591908A (en) Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma
BR122018016045B8 (pt) proteína variante otimizada
NO20075103L (no) Antistoffer og relaterte molekyler som bindes til 161P2F10B proteiner
NO994983D0 (no) Fremgangsmåte for fremstilling av anti-humane antigenreseptorer, samt anvendelse av disse
WO2006073748A3 (en) Antibodies against antigen presenting cells and uses thereof
WO2004091543A3 (en) Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells
ATE419008T1 (de) Adjuvante zusammensetzung und anwendungsverfahren dafür
WO2013177214A3 (en) Epitope focusing by variable effective antigen surface concentration
WO2005028510A3 (en) Methods, kits, and compositions for the development and use of monoclonal antibodies specific to antigens of low immunogenicity
ES2177927T3 (es) Composicion para provocar una reaccion inmunologica a un determinante antigenico no proteinico.
WO2006067635A3 (en) USE OF Ϝδ T LYMPHOCYTE ACTIVATORS AS VACCINE ADJUVANT
WO2005000884A8 (en) Poly-gamma-glutamic conjugates for eliciting immune responses directed against bacilli
NO20053363L (no) Malrettede enkle epitoper.
WO1999013907A3 (en) Methods to improve immunogenicity of antigens and specificity of antibodies
NO20052714L (no) Fremgangsmater og materialer for behandling av inflammatoriske tilstander
WO2006000787A3 (en) Antibodies against bacterial antigens and their use in the generation of immune responses against apoptotic cells
MX2023005570A (es) Anticuerpos conjugados o fusionados al dominio de union del receptor de la proteina de la espicula de sars-cov-2 y usos de los mismos con fines de vacunacion.
CL2022002635A1 (es) Péptidos de dominios knob autónomos
WO2004031358A3 (en) Genetically engineered p30 antigen, improved antigen cocktail, and uses thereof

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application